«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年04期

页码:

291-293

栏目:

出版日期:

2018-07-20

文章信息/Info

Title:

Effects of atorvastatin on late sodium current in ventricular myocytes in rats suffering from simulated ischemia

作者:

李小龙; 万 征

天津医科大学总医院心内科，天津300052

Author(s):

LI Xiao-long; WAN Zheng

Department of Cardiology，General Hospital，Tianjin Medical University,Tianjin 300052，China

关键词:

模拟缺血; 晚钠电流; 阿托伐他汀; 膜片钳

Keywords:

simulated ischemia;  late sodium current;  atorvastatin;  patch clamp

分类号:

R331.3+8

DOI:

-

文献标志码:

Ａ

摘要:

目的：观察不同模拟缺血时间下大鼠左室心肌细胞晚钠电流（INaL）的变化规律及阿托伐他汀对该过程的作用。方法：Wistar大鼠共40只，分离左室心肌细胞，分为正常组、缺血组、正常-他汀组和缺血-他汀组。用全细胞膜片钳分别记录4组细胞基线状态下INaL，再灌流3 min后，每2 min记录1次，记录10 min，观察INaL的变化规律。计算I/Imax作为标准化INaL，比较4组INaL标准化值。结果：取-40 mV测试电压下，（１）正常组，基线状态和记录3、5、7、9 min 4个时间点的INaL分别为1、0.82±0.24、1.00±0.36、0.92±0.32和1.03±0.38，各记录时间点与基线之间均无差别（分别P>0.05）；（２）缺血组，基线状态INaL为1，在模拟缺血3～7 min时，INaL增大，并于3 min时达峰（1.79±0.66）；（３）正常-他汀组，基线状态和4个记录时间点的INaL分别为1、0.88±0.28、1.06±0.23、1.03±0.27和0.94±0.19，各记录时间点与基线之间均无差别（分别P>0.05）；（４）缺血-他汀组，与基线状态相比，模拟缺血3 min时的INaL无变化，5 min时较基线值减少0.43±0.31（P=0.035），7 min时较基线值减少0.48±0.37（P=0.044）；（５）在模拟缺血3 min时，相比于正常组，缺血组INaL增大（P=0.001）；相比于缺血组，缺血-他汀组INaL则减小（P=0.004）；正常组和缺血-他汀组的INaL之间并无差别（P>0.05）。结论：模拟缺血早期（10 min内）心室肌细胞INaL呈时间依赖性增大；5 μmol/L阿托伐他汀不改变正常状态下的INaL，却可抑制缺血状态下INaL的异常增大。

Abstract:

Objective: To observe the changes of late sodium current (INaL) in left ventricular myocytes in rats suffering simulated ischemia at different time points and the effect of atorvastatin on that process. Methods: Left ventricular myocytes were isolated from forty wistar rats and randomly divided into normal group, ischemia group, normal-statin group and ischemia-statin group. Firstly, baseline INaL of all cells were recorded by whole-cell patch clamp. Secondly, cells were perfused for 3 min. Finally, INaL was recorded once every 2 min.The recording time was totally 10 min. The changes of INaL were observed. I/Imax was calculated as the standardized value of INaL. Standardized values of INaL of four groups were compared. Results: At the testing potential of -40 mV,（1）normal group, INaL of baseline and four time points was 1, 0.82±0.24, 1.00±0.36, 0.92±0.32 and 1.03±0.38, respectively; there was no significant difference between baseline and different time points(P>0.05, respectively);（2）ischemia group, INaL of baseline was 1; INaL was increased during 3～7 min of simulated ischemia, reaching the peak at 3 min (1.79±0.66); （3）normal-statin group, INaL of baseline and four time points was 1, 0.88±0.28, 1.06±0.23, 1.03±0.27 and 0.94±0.19, respectively; there was no significant difference between baseline and different time points(P>0.05), respectively);（4）ischemia-statin group, compared with the baseline value, INaL at 3 min of simulated ischemia didn’t change, INaL at 5 min reduced by 0.43±0.31(P=0.035), INaL at 7 min reduced by 0.48±0.37 (P=0.044);（5）at 3 min of simulated ischemia: compared with normal group, INaL of ischemia group increased (P=0.001); compared with ischemia group, INaL of ischemia-statin group decreased(P=0.004), and there was no difference between normal group and ischemia-statin group (P>0.05). Conclusion: INaL of ventricular myocytes increases in a time-dependent manner at the early stage of simulated ischemia (10 min), and 5μmol/L atorvastatin does not change INaL in normal state but could inhibit the abnormal increase of INaL in ischemic state.

参考文献/References:

[1] 王立祥，孟庆义，余涛. 2016中国心肺复苏专家共识[J]. 中华危重病急救医学,2016,28(12):1059
[2] Ramasubbu K, Estep J, White D L, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy[J]. J Am Coll Cardiol,2008,51(4):415
[3] Venturi E, Lindsay C, Lotteau S, et al. Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform[J]. Br J Pharmacol, 2018, 175（6）：938
[4] Undrovinas A I, Fleidervish I A, Makielski J C. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine[J]. Circ Res,1992, 71(5):1231
[5] Justo F, Fuller H, Nearing B D, et al. Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation[J]. Heart Rhythm,2016,13(9):1860
[6] 李洪仕，万征，边波，等. 阿托伐他汀对大鼠左室心肌细胞瞬时钠通道电流的作用[J]. 中国心脏起搏与心电生理杂志,2009, 23(5):420
[7] Chadda K R, Jeevaratnam K, Lei M, et al. Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes[J]. Pflugers Arch, 2017, 469(5/6):629
[8] 李洪仕，边波，万征，等. 心室快钠电流在不同模拟缺血时间的变化及阿托伐他汀的作用[J]. 中国心脏起搏与心电生理杂志,2011, 25(1):61
[9] Song Y, Shryock J C, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes[J]. J Cardiovasc Pharmacol, 2004, 44(2):192
[10] Antzelevitch C, Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis[J]. J Cardiovasc Electrophysiol, 2006, 17 Suppl 1:S79
[11] Morita N, Lee J H, Xie Y, et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine[J]. J Am Coll Cardiol, 2011, 57(3):366
[12] 赵青，李洪仕，万征，等. 阿托伐他汀对大鼠模拟缺血左室心肌细胞瞬时外向钾电流的作用[J]. 中国心脏起搏与心电生理杂志,2011, 25(5):426
[13] Belardinelli L, Giles W R, Rajamani S, et al. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress[J]. Heart Rhythm, 2015, 12(2):440
[14] Wang X J, Wang L L, Fu C, et al. Ranolazine attenuates the enhanced reverse Na(+)-Ca(2)(+) exchange current via inhibiting hypoxia-increased late sodium current in ventricular myocytes[J]. J Pharmacol Sci, 2014, 124(3):365
[15] Liu C W, Yang F, Cheng S Z, et al. Rosuvastatin postconditioning protects isolated hearts against ischemia-reperfusion injury: The role of radical oxygen species, PI3K-Akt-GSK-3beta pathway, and mitochondrial permeability transition pore[J]. Cardiovasc Ther, 2017, 35(1):3
[16] Wang F, Ma H, Liang W J, et al. Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors[J]. Oncotarget, 2017, 8(6):9021
[17] Kisvari G, Kovacs M, Seprenyi G, et al. The activation of PI 3-kinase/Akt pathway is involved in the acute effects of simvastatin against ischaemia and reperfusion-induced arrhythmias in anaesthetised dogs[J]. Eur J Pharmacol, 2015, 769:185

相似文献/References:

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 2018-07-20